Telik, Inc. (TELK) is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Telik’s product candidates are: TELINTRA® (TLK199) is in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia TELCYTA® (TLK286) is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase …Read More